Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-19T04:53:52.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Adjunctive use of reboxetine in schizophrenia

Published online by Cambridge University Press:  16 April 2020

Thomas J. Raedler ,
Holger Jahn ,
Josef Arlt ,
Falk Kiefer ,
Mildred Schick ,
Dieter Naber  and
Klaus Wiedemann
Thomas J. Raedler*
Affiliation:
University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246Hamburg, Germany
Holger Jahn
Affiliation:
University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246Hamburg, Germany
Josef Arlt
Affiliation:
University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246Hamburg, Germany
Falk Kiefer
Affiliation:
University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246Hamburg, Germany
Mildred Schick
Affiliation:
University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246Hamburg, Germany
Dieter Naber
Affiliation:
University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246Hamburg, Germany
Klaus Wiedemann
Affiliation:
University Hospital Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martini str. 52, 20246Hamburg, Germany
*
*Corresponding author. Email address: traedler@uke.uni-hamburg.de (T.J. Raedler).
Get access

Abstract

Background

Schizophrenia is frequently complicated by depressive or negative symptoms that respond only moderately to treatment with antipsychotic drugs. Reboxetine is a novel antidepressant, which inhibits the reuptake of norepinephrine. We sought to study the efficacy and tolerability of the adjunctive use of reboxetine in a cohort of schizophrenic patients with prominent depressive or negative symptoms.

Methods

Sixteen schizophrenic inpatients were recruited for this study. All subjects received 4–8 mg of reboxetine/day while the antipsychotic medication (typical antipsychotics = 4; atypical antipsychotics = 12) was continued. All subjects underwent a standardized assessment including PANSS, CGI, HAMD, and CDSS before and after treatment with reboxetine (mean 26 ± 17 d).

Results

All subjects tolerated treatment with reboxetine. Adverse effects were mild and did not require discontinuation of reboxetine. All clinical scores (PANSS 93.1 vs. 63.1; CGI 5.4 vs. 4.1; HAMD 20.4 vs. 8.1; CDSS 12.5 vs. 4.6) improved significantly under adjunctive treatment with reboxetine (all P < 0.01).

Conclusion

The adjunctive use of reboxetine in schizophrenic patients was safe and well-tolerated. Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia.

Keywords

SchizophreniaDepressionNegative symptomsAntidepressantsReboxetine
Type
Original article
Information
European Psychiatry , Volume 19 , Issue 6 , September 2004 , pp. 366 - 369
Copyright
Copyright © 2004 European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, DAddington, JSchissel, B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247–51.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(Suppl):1–63.CrossRefGoogle Scholar
Baynes, DMulholland, CCooper, SJMontgomery, RCMacFlynn, GLynch, G, et al. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 2000;45:47–56.CrossRefGoogle ScholarPubMed
Berk, MIchim, CBrook, S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001;16:87–92.CrossRefGoogle ScholarPubMed
Bermanzohn, PCPorto, LArlow, PBPollack, SStronger, RSiris, SG. Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occuring syndromes. Schizophr Bull 2000;26:517–25.CrossRefGoogle Scholar
Goff, DCMidha, KKSarid-Segal, OHubbard, JWAmico, E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995;117:417–23.CrossRefGoogle ScholarPubMed
Green, MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321–30.Google Scholar
Guy, W. ECDEU Assessment Manual for Psychopharmacology, 338. Washington, DC: US Department of Health and Welfare; 1976. p. 534–7.Google Scholar
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.CrossRefGoogle ScholarPubMed
Heilä, HIsometsä, ETHenriksson, MMHeikkinen, MEMarttunen, MJLönnqvist, JK. Suicide and schizophrenia: a nation-wide psychological autopsy study on age-and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997;154:1235–42.Google Scholar
Hogarty, GEMcEvoy, JPUlrich, RFDiBarry, ALBartone, PCooley, S, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995;52:29–41.CrossRefGoogle ScholarPubMed
Kay, SROpler, LAFiszbein, A. Positive and negative symptoms in schizophrenia: assessment and research. New York: Bruner Mazel; 1991.Google Scholar
Lancon, CAuquier, PReine, GBernard, DAddington, D. Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. Schizophr Res 2001;47:135–40.CrossRefGoogle ScholarPubMed
Levinson, DFUmapathy, CMusthaq, M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999;156:1138–48.Google ScholarPubMed
Linner, LEndersz, HOhman, DBengtsson, FSchalling, MSvensson, TH. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 2001;297:540–6.Google ScholarPubMed
Massana, JMoller, HJBurrows, GDMontenegro, RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73–80.CrossRefGoogle ScholarPubMed
Poyurovsky, MIsaacs, IFuchs, CSchneidman, MFaragian, SWeizman, R, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:297–302.CrossRefGoogle ScholarPubMed
Sands, JRHarrow, M. Depression during the longitudinal course of schizophrenia. Schizophr Bull 1999;25:157–71.CrossRefGoogle ScholarPubMed
Schutz, GBerk, M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001;16:275–8.CrossRefGoogle ScholarPubMed
Silver, HBarash, IAharon, NKaplan, APoyurovsky, M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 2000;15:257–61.CrossRefGoogle ScholarPubMed
Siris, SGMason, SEBermanzohn, PCAlvir, JMMcCorry, TA. Adjunctive imipramine maintenance in postpsychotic depression/ negative symptoms. Psychopharmacol Bull 1990;26:91–4.Google ScholarPubMed
Siris, SG. Depression in Schizophrenia. In: Hirsch, SRWeinberger, DR, editors. Schizophrenia. Oxford: Blackwell Science Ltd; 1995. p. 128–46.Google Scholar
Siris, SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry 2000;157:1379–89.CrossRefGoogle ScholarPubMed
Taiminen, TJSyvalahti, ESaarijarvi, SNiemi, HLehto, HAhola, V, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol 1997;12:31–5.CrossRefGoogle Scholar
Thakore, JHBerti, CDinan, TG. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand 1996;94:194–7.CrossRefGoogle ScholarPubMed
Tollefson, GDSanger, TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466–74.Google ScholarPubMed
Weickert, TWGoldberg, TEGold, JMBigelow, LBEgan, MFWeinberger, DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000;57:907–13.CrossRefGoogle ScholarPubMed
Wong, EHSonders, MSAmara, SGTinholt, PMPiercey, MFHoffmann, WP, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000;47:818–29.CrossRefGoogle ScholarPubMed
Zisook, SMcAdams, LAKuck, JHarris, MJBailey, APatterson, TL, et al. Depressive symptoms in schizophrenia. Am J Psychiatry 1999;156:1736–43.Google Scholar
Submit a response

Comments

No Comments have been published for this article.